DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia

David G. J. Cucchi, Christian M. Vonk, Melissa Rijken, François G. Kavelaars, Pauline A. Merle, Elvira Verhoef, Bianca Venniker-Punt, Zinia J. Kwidama, Patrycja Gradowska, Bob L€ owenberg, Jeroen J. W. M. Janssen, Jacqueline Cloos, and Peter J. M. Valk Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and Department of Hematology, Erasmus Medical Center Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands

[1]  E. Vellenga,et al.  Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. , 2021, Blood advances.

[2]  G. Ossenkoppele,et al.  Two decades of targeted therapies in acute myeloid leukemia , 2021, Leukemia.

[3]  H. Kantarjian,et al.  Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia , 2020, Blood Cancer Journal.

[4]  R. Larson,et al.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.

[5]  Hong-jie Shen,et al.  Impact of FLT3-ITD length on prognosis of acute myeloid leukemia , 2018, Haematologica.

[6]  J. Philippé,et al.  RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. , 2018, Blood.

[7]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[8]  E. Vellenga,et al.  Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. , 2017, Blood.

[9]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[10]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[11]  P. Starostik,et al.  Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia , 2014, Leukemia research reports.

[12]  R. Kusec,et al.  More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML). , 2006, Blood.

[13]  Jeremy W. Linsley,et al.  Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. , 2006, Blood.

[14]  F. Locatelli,et al.  Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group , 2017, Leukemia.